BioPharma Dive September 12, 2023
The two-year-old San Diego biotech is allied with The Jackson Laboratory to engineer better mouse models of the rare diseases it plans to target.
A new biotechnology startup is getting help from an unusual partner in its attempt to develop rare disease drugs that could also treat more common conditions.
Actio Biosciences, which launched Tuesday with $55 million in venture funding, is working with The Jackson Laboratory to engineer mouse models that better recapitulate diseases, potentially allowing Actio scientists to more accurately vet would-be drugs.
The Bar Harbor, Maine-based Jackson, or Jax — a top supplier of lab mice — helped develop an animal model Actio is using to study a target called TRPV4. The San Diego startup believes TRPV4,...
Today's Sponsors
Today's Sponsor